Breaking News Instant updates and real-time market news.

PTCT

PTC Therapeutics

$13.34

-0.25 (-1.84%)

15:57
10/10/16
10/10
15:57
10/10/16
15:57

PTC Therapeutics' BMI1 inhibitor PTC596 said to report 0% ORR

Widely followed biotech investor @AndyBiotech tweeted that PTC Therapeutics' BMI1 inhibitor PTC596 had its first data disclosure at ESMO, reporting a "Big fat 0% ORR, not even 1 SD... Another blow to cancer stem cell theory?" Reference Link

  • 06

    Nov

PTCT PTC Therapeutics
$13.34

-0.25 (-1.84%)

07/20/16
WEDB
07/20/16
NO CHANGE
Target $12
WEDB
Neutral
Wedbush staying on sidelines on PTC Therapeutics after NICE issues guidance
Noting that NICE has finalized access for England for PTC Therapeutics' Translarna, Wedbush analyst Heather Behanna said she remains on the sidelines on PTC shares, citing the drug's continued regulatory and pricing risks in Europe. While keeping a Neutral rating and $12 price target on PTC shares, Behanna said she believes it is unlikely that the EMA will pull the drug from the market and sees "meaningful upside" in early 2017 if Translarna can demonstrate a statistically significant positive result in cystic fibrosis.
07/26/16
FBCO
07/26/16
DOWNGRADE
Target $6
FBCO
Neutral
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Alethia Young downgraded PTC Therapeutics to Neutral and lowered its price target to $6 from $12 citing further uncertainty around the Eurozone DMD approval case. Following the company's release, Young believes that the approval timelines in EU at the best case are now longer than his original expectations though the drug does remain on the market and lowered his probability of success in EMA to 75% from $100.
09/20/16
JEFF
09/20/16
NO CHANGE
Target $7
JEFF
Hold
Jefferies thinks eteplirsen approval will have limited impact on PTC
Jefferies analyst Gena Wang believes yesterday's FDA approval of Sarepta Therapeutics' (SRPT) eteplirsen will have a limited impact on PTC Therapeutics (PTCT). While PTC's potential treatment for Duchenne muscular dystrophy ataluren is considered safe, the FDA approval of eteplirsen is mainly based on the marginal increase of dystrophin level and PTC does not have any dystrophin data from Phase 3, Wang tells investors in a research note. Eteplirsen's approval could pressure the FDA to reconsider the review progress of ataluren, but the final outcome would likely remain the same, the analyst contends. She keeps a Hold rating on PTC with a $7 price target. The stock closed yesterday up 21%, or $1.88, to $10.99.
10/03/16
BOFA
10/03/16
NO CHANGE
Target $15
BOFA
Buy
PTC Therapeutics price target raised to $15 from $9 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised PTC Therapeutics' price target to $15 from $9 following partner Roche's recruitment for a trial it is conducting to investigate a potential treatment for Spinal Muscular Atrophy, or SMA, patients. Given this advancement, the analyst is raising his probability of approval to 30% from 20% in SMA and maintains his Neutral rating.

TODAY'S FREE FLY STORIES

SHO

Sunstone Hotel

$15.93

0.16 (1.01%)

08:08
09/21/17
09/21
08:08
09/21/17
08:08
Hot Stocks
Sunstone Hotel provides update on impact from Hurricanes Harvey Irma »

Sunstone Hotel provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$37.23

-2 (-5.10%)

08:07
09/21/17
09/21
08:07
09/21/17
08:07
Recommendations
L Brands analyst commentary  »

Victoria's Secret…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.74

0.62 (4.73%)

, NVDA

Nvidia

$185.84

-1.51 (-0.81%)

08:05
09/21/17
09/21
08:05
09/21/17
08:05
Recommendations
AMD, Nvidia, Tesla analyst commentary  »

Tesla shift to AMD from…

AMD

AMD

$13.74

0.62 (4.73%)

NVDA

Nvidia

$185.84

-1.51 (-0.81%)

TSLA

Tesla

$373.91

-1.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

ALNY

Alnylam

$113.84

38.8 (51.71%)

08:05
09/21/17
09/21
08:05
09/21/17
08:05
Recommendations
Alnylam analyst commentary  »

Alnylam data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
09/21/17
09/21
08:05
09/21/17
08:05
General news
Canada wholesale trade report preview »

Canada wholesale trade…

BHGE

Baker Hughes

$37.50

0.11 (0.29%)

08:04
09/21/17
09/21
08:04
09/21/17
08:04
Recommendations
Baker Hughes analyst commentary  »

Baker Hughes 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 20

    Oct

SCG

Scana

$57.80

-0.41 (-0.70%)

08:04
09/21/17
09/21
08:04
09/21/17
08:04
Hot Stocks
Scana receives subpoena for documents relating to nuclear project »

Scana announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TANH

Tantech Holdings

$4.07

0.08 (2.01%)

08:03
09/21/17
09/21
08:03
09/21/17
08:03
Hot Stocks
Tantech Holdings awarded $20M in electric van and bus sales orders »

Tantech Holdings'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VR

Validus

$46.93

1.2 (2.62%)

08:03
09/21/17
09/21
08:03
09/21/17
08:03
Recommendations
Validus analyst commentary  »

Validus net exposure to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOLD

Audentes Therapeutics

$26.57

1.04 (4.07%)

08:02
09/21/17
09/21
08:02
09/21/17
08:02
Hot Stocks
Audentes Therapeutics doses first patient in ASPIRO trial »

Audentes Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELGX

Endologix

$4.29

-0.15 (-3.38%)

08:01
09/21/17
09/21
08:01
09/21/17
08:01
Hot Stocks
Endologix announces CE Mark approval for Nellix system »

Endologix announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$156.07

-2.66 (-1.68%)

08:00
09/21/17
09/21
08:00
09/21/17
08:00
Options
Apple call buyer realizes 32% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

08:00
09/21/17
09/21
08:00
09/21/17
08:00
General news
Treasury Market Outlook: bonds remain mostly weaker »

Treasury Market Outlook:…

NVDA

Nvidia

, TSLA

Tesla

07:58
09/21/17
09/21
07:58
09/21/17
07:58
Technical Analysis
Technical View: AMD trades up on report it is working with Tesla on AI chip »

In the pre-market the AMD…

NVDA

Nvidia

TSLA

Tesla

AMD

AMD

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

JAKK

JAKKS Pacific

$3.15

0.325 (11.50%)

07:56
09/21/17
09/21
07:56
09/21/17
07:56
Downgrade
JAKKS Pacific rating change  »

JAKKS Pacific downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCL

Royal Caribbean

$114.94

-2.98 (-2.53%)

07:56
09/21/17
09/21
07:56
09/21/17
07:56
Conference/Events
Royal Caribbean management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RMBS

Rambus

$13.35

-0.23 (-1.69%)

07:55
09/21/17
09/21
07:55
09/21/17
07:55
Conference/Events
Rambus to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Oct

MO

Altria Group

$61.22

-1.01 (-1.62%)

07:54
09/21/17
09/21
07:54
09/21/17
07:54
Recommendations
Altria Group analyst commentary  »

Altria cigarette price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCO

Moody's

$136.77

0.03 (0.02%)

07:50
09/21/17
09/21
07:50
09/21/17
07:50
Conference/Events
Moody's management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

LII

Lennox

$170.37

4.54 (2.74%)

07:49
09/21/17
09/21
07:49
09/21/17
07:49
Conference/Events
Lennox management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

APRN

Blue Apron

$5.22

-0.29 (-5.26%)

07:49
09/21/17
09/21
07:49
09/21/17
07:49
Technical Analysis
Technical View: Blue Apron trades highe as Plated acquired by Albertsons »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIVI

II-VI

07:48
09/21/17
09/21
07:48
09/21/17
07:48
Conference/Events
II-VI management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 28

    Sep

  • 13

    Nov

HSC

Harsco

$19.70

-0.2 (-1.01%)

07:47
09/21/17
09/21
07:47
09/21/17
07:47
Conference/Events
Harsco management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

TXN

Texas Instruments

$85.83

-0.98 (-1.13%)

07:44
09/21/17
09/21
07:44
09/21/17
07:44
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$438.17

6.79 (1.57%)

, AMGN

Amgen

$188.17

1.85 (0.99%)

07:44
09/21/17
09/21
07:44
09/21/17
07:44
Recommendations
Regeneron, Amgen, AstraZeneca, AbbVie analyst commentary  »

Regeneron price target…

REGN

Regeneron

$438.17

6.79 (1.57%)

AMGN

Amgen

$188.17

1.85 (0.99%)

AZN

AstraZeneca

$32.93

0.26 (0.80%)

ABBV

AbbVie

$87.41

1.04 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.